Oncorus Stock Fundamentals
| ONCRDelisted Stock | USD 0.04 0.01 14.71% |
Oncorus fundamentals help investors to digest information that contributes to Oncorus' financial success or failures. It also enables traders to predict the movement of Oncorus Stock. The fundamental analysis module provides a way to measure Oncorus' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Oncorus stock.
Oncorus |
Oncorus Company Return On Equity Analysis
Oncorus' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Oncorus Return On Equity | -1.25 |
Most of Oncorus' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Oncorus is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Oncorus has a Return On Equity of -1.2456. This is 94.8% lower than that of the Healthcare sector and 96.58% lower than that of the Biotechnology industry. The return on equity for all United States stocks is notably higher than that of the company.
Oncorus Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Oncorus's current stock value. Our valuation model uses many indicators to compare Oncorus value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Oncorus competition to find correlations between indicators driving Oncorus's intrinsic value. More Info.Oncorus is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Oncorus by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Oncorus Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oncorus' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Oncorus could also be used in its relative valuation, which is a method of valuing Oncorus by comparing valuation metrics of similar companies.Oncorus is currently under evaluation in return on equity category among its peers.
Oncorus Fundamentals
| Return On Equity | -1.25 | |||
| Return On Asset | -0.32 | |||
| Current Valuation | 25.71 M | |||
| Shares Outstanding | 26.09 M | |||
| Shares Owned By Insiders | 12.69 % | |||
| Shares Owned By Institutions | 55.29 % | |||
| Number Of Shares Shorted | 447.72 K | |||
| Price To Book | 0.13 X | |||
| EBITDA | (75.42 M) | |||
| Net Income | (77.42 M) | |||
| Cash And Equivalents | 100.24 M | |||
| Cash Per Share | 3.86 X | |||
| Total Debt | 70.65 M | |||
| Debt To Equity | 0.72 % | |||
| Current Ratio | 6.42 X | |||
| Book Value Per Share | 1.19 X | |||
| Cash Flow From Operations | (61.69 M) | |||
| Short Ratio | 0.74 X | |||
| Earnings Per Share | (5.49) X | |||
| Target Price | 5.0 | |||
| Number Of Employees | 64 | |||
| Beta | 2.85 | |||
| Market Capitalization | 3.15 M | |||
| Total Asset | 145.59 M | |||
| Retained Earnings | (272.01 M) | |||
| Working Capital | 27.41 M | |||
| Z Score | -4.07 | |||
| Net Asset | 145.59 M |
About Oncorus Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oncorus's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oncorus using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oncorus based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Oncorus operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in Oncorus Stock
If you are still planning to invest in Oncorus check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oncorus' history and understand the potential risks before investing.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| CEOs Directory Screen CEOs from public companies around the world | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |